Related news for: Dr Stefan Blum
Mater researchers have shown that new applications of existing drugs has the potential to improve quality of life for people with Myasthenia gravis
New applications of drugs could reduce side effects for Myasthenia gravis patients
Mater's Neurosciences Unit are investigating novel diagnostic markers for autoimmune encephalitis
NMDAR antibody encephalitis and novel diagnostic markers